Navidea Biopharmaceuticals Second Quarter 2012 Earnings and Business Update Conference Call Invitation
Conference Call Scheduled for 8:00 AM EDT, Tuesday, August 7th
DUBLIN, Ohio--(BUSINESS WIRE)-- Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that the Company will report its financial results for the second quarter of 2012 on Monday, August 6, 2012 after market close. The announcement of results will be followed by a conference call with the investment community, Tuesday, August 7, 2012 at 8:00 AM EDT.
Navidea's President and CEO, Dr. Mark Pykett, Executive Vice President and Chief Business Officer, Dr. Thomas Tulip, and CFO, Brent Larson, will provide a development and business update and will discuss the Company's financial results for the second quarter of 2012 during the conference call. The conference call can be accessed as follows:
| CONFERENCE CALL INFORMATION | ||||||||||||
| TO PARTICIPATE LIVE: | TO LISTEN TO A REPLAY: | |||||||||||
| Date: | August 7, 2012 | Available until: | August 21, 2012 | |||||||||
| Time: | 8:00 AM EDT |
Toll-free (U.S.) Dial in # : |
(877) 660-6853 | |||||||||
|
International Dial in # : |
(201) 612-7415 | |||||||||||
|
Toll-free (U.S.) Dial in # : |
(877) 407-8033 |
|
||||||||||
| International Dial in # : | (201) 689-8033 |
Replay passcode: |
||||||||||
|
Account # |
286 | |||||||||||
|
Conference ID #: |
398463 | |||||||||||
About Navidea Biopharmaceuticals, Inc.
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a biopharmaceutical company focused on the development and commercialization of precision diagnostics and radiopharmaceutical agents. Navidea is actively developing three radiopharmaceutical agent platforms – Lymphoseek®, AZD4694 and RIGScanTM – to help identify the sites and pathways of undetected disease and enable better diagnostic accuracy, clinical decision-making and ultimately patient care. Navidea’s strategy is to deliver superior growth and shareholder return by bringing to market novel radiopharmaceutical agents and advancing the Company’s pipeline through selective acquisitions, global partnering and commercialization efforts. For more information, please visit www.navidea.com.
Navidea Biopharmaceuticals, Inc.
Brent Larson,
614-822-2330
Sr. VP & CFO
Source: Navidea Biopharmaceuticals, Inc.
Released July 30, 2012